Themis Bioscience Revenue and Competitors
Estimated Revenue & Valuation
- Themis Bioscience's estimated annual revenue is currently $6.9M per year.
- Themis Bioscience's estimated revenue per employee is $117,000
Employee Data
- Themis Bioscience has 59 Employees.
- Themis Bioscience grew their employee count by 2% last year.
Themis Bioscience's People
| Name | Title | Email/Phone |
|---|
Themis Bioscience Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.8M | 27 | -4% | $15.7M | N/A |
#2 | $25.5M | 178 | -3% | N/A | N/A |
#3 | $1.4M | 22 | -50% | $21.2M | N/A |
#4 | $56.6M | 348 | 19% | $6M | N/A |
#5 | $6.3M | 56 | -21% | $216.8M | N/A |
#6 | $0M | 2 | 0% | $33.3M | N/A |
#7 | $33.3M | 233 | 0% | N/A | N/A |
#8 | $32.4M | 232 | -26% | $64.6M | N/A |
#9 | $30M | 215 | -22% | $46.8M | N/A |
#10 | $261.6M | 1407 | 15% | $75M | N/A |
What Is Themis Bioscience?
Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications. Exploiting the full potential of our proprietary Themaxyn® platform we are able to identify and rapidly advance vaccine candidates at various stages of development. Based on a well-proven base technology, the Themaxyn® platform offers both, an excellent safety profile and a validated manufacturing process. Themis Bioscience was founded in 2009 by a group of internationally renowned vaccine and biotech executives in Vienna, Austria. In 2014 Themis successfully completed a phase I clinical trial with our Chikungunya vaccine in Austria. Themis continues to head the race for preventing emerging infectious diseases and started a phase II clinical trial with our Chikungunya vaccine in 2016 and a phase I clinical trial with our Zika vaccine in 2017.
keywords:N/A
N/A
Total Funding
59
Number of Employees
$6.9M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Themis Bioscience News
... And Forecast | Emergent BioSolutions, Valneva, Moderna, Novavax, Johnson & Johnson, Themis Bioscience, Sanofi, IMV, Takeda Pharmaceutical, CaroGen.
iBio; Themis Bioscience; Arbovax; Janssen Yellow Fever Treatment Market Breakdown by Type: Vaccine; Oral Rehydration; Pain Management...
As an executive, I have built companies like Nabriva, Themis Bioscience, and PDC Biotech. Phil Morle and his 4 No-Go's. He is a Partner at the...
Other Companies in Vienna
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 59 | 11% | N/A |
#2 | $13.9M | 59 | -20% | N/A |
#3 | $20.5M | 59 | 1375% | N/A |
#4 | $16.7M | 60 | 5% | $31M |
#5 | $11.3M | 60 | 20% | N/A |